Sofia Isabel Quezada-Ramirez

Dr. Sofia Isabel Quezada-Ramirez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2025 in Biomedicines
Verified
Journal Article
Open access
MMMichelle Morcos-Sandino
Michelle Morcos-Sandino
Sofia Isabel Quezada-RamirezSofia Isabel Quezada-Ramirez
Sofia Isabel Quezada-Ramirez
ALAndrés Gómez-De León
Andrés Gómez-De León
Acute myeloid leukemia (AML) presents a significant global health challenge due to its aggressive behavior and mortality rates. Traditionally, AML treatment has relied on intensive chemotherapy—anthracyclines and cytarabine. However, recent breakthroughs in targeted therapies are transforming clinical practices. This review examines current treatment strategies, including breakthrough therapies. Also, a global perspective on AML management includes the disparity in treatment availability, particularly the difficulties faced by low- and middle-income countries due to the high cost and restricted access to novel therapies.

1 April 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
RSRosario Salazar-Riojas
Rosario Salazar-Riojas
DADalila M. Alvarado-Navarro
Dalila M. Alvarado-Navarro
YCYair O. Chávez-Estrada
Yair O. Chávez-Estrada
AHAna K. Hernández-Navarro
Ana K. Hernández-Navarro
MAMartha B. Ake-Uc
Martha B. Ake-Uc
ALAndrés Gómez-De León
Andrés Gómez-De León
PURPOSE: To validate and replicate an automated decentralized CD19 chimeric antigen receptor T (CAR-T) cell manufacturing process from healthy adult volunteers in an academic institution in a middle-income country. METHODS: Healthy volunteers were recruited and underwent leukapheresis with the continuous mononuclear cell (MNC) collection protocol. Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory domain. Quality control was assessed at different points in the production process with prespecified release criteria including product's aspect, sterility, cell viability, impurity, and quantity. The target dose formulation was 1 × 10 6 /kg viable CAR-T cells per volunteer. RESULTS: Five healthy volunteers were recruited, all donated adequate MNC units, and successfully underwent the manufacturing process. After T-cell culture harvest, the products contained a median CAR-T cell concentration of 16.5 × 10 6 /mL (range, 7.7-22.2 × 10 6 /mL), with a median transduction percentage of 44.7% (range, 39.2%-60.5%) and a median CD3 + cell viability of 97.7% (range, 90.4%-98.7%). Sterility was maintained throughout the manufacturing process. The quantity of cells harvested per kilogram of body weight was 24.6 MB-CART19.1 cells × 10 6 /kg (range, 9.3-33.1 × 10 6 /mL). The quality was similar in both fresh and cryopreserved units. Dose formulations were 1.1 CAR-T cells × 10 6 /kg (range, 1.0-1.2 CAR-T cells × 10 6 /kg). CONCLUSION: Our study demonstrates an effective methodology with satisfactory and comparable performance to international reports. Point-of-care manufacturing is a feasible alternative to increase access to CAR-T cells in academic centers.

13 September 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
Sofia Isabel Quezada-RamirezSofia Isabel Quezada-Ramirez
Sofia Isabel Quezada-Ramirez
JMJosé Emiliano Montelongo-Cepeda
José Emiliano Montelongo-Cepeda
HVHector A. Vaquera-Alfaro
Hector A. Vaquera-Alfaro
RSRosario Salazar-Riojas
Rosario Salazar-Riojas
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Hematopoietic stem cell transplantation (SCT) offers curative potential for hematologic diseases but demands rigorous quality management often out of reach in low- and middle-income countries (LMICs). Our institution- the only public academic hospital in Latin America accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) since 2016, with recertifications in 2020 and 2024-has demonstrated that FACT standards can be met through pragmatic, cost-effective adaptations. This review summarizes key strategies for continued maintenance of high-quality transplantation practices, including data management, continuous medical education, as well as cost-effective clinical practices. We also address donor selection approaches, cryopreservation alternatives, and supplementary accreditations. By outlining our FACT accreditation journey and outcomes equivalent to conventional settings, we provide a replicable framework for LMIC centers to achieve international quality benchmarks. Our experience underscores that high-quality SCT and sustained accreditation are attainable in resource-constrained environments, ultimately improving access and survival for patients across the LMICs.

15 April 2025 in Expert Review of Hematology
Verified
Journal Article
Closed access
Sofia Isabel Quezada-RamirezSofia Isabel Quezada-Ramirez
Sofia Isabel Quezada-Ramirez
LTLuz Del Carmen Tarín-Arzaga
Luz Del Carmen Tarín-Arzaga
ALAndrés Gómez-De León
Andrés Gómez-De León
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Multiple myeloma (MM) therapy has greatly evolved over the last decade. Immunomodulators and anti-CD38 antibodies have reshaped the therapeutic landscape. Nevertheless, relapses occur with worsening prognosis each relapse. Achieving deep responses in first-line treatment is key to reducing future disease burden. To advance patient outcomes, current regimens must be continuously refined through personalization, incorporation of biomarkers to guide therapy, and novel drugs. This review aims to assess existing therapies and investigate how integrating novel drug combinations and biomarker-driven approaches can improve efficacy and tolerability for newly diagnosed multiple myeloma (NDMM) patients. Meta-analysis, systematic reviews, original articles and real-world studies were included in this review. Databases searched included PubMed, Scopus, and Google Scholar from inception until February 2025. Discerning the best therapy sequence is a challenge for NDMM individuals. Minimal residual disease assessment is becoming a pivotal tool for guiding therapeutic approaches to enhance outcomes and tolerability. Emerging evidence supports early use of potent therapies - such as next-generation anti-CD38 antibodies and CELMoDs - to achieve deeper, more durable responses and possibly delay relapses. Immunotherapies like bispecific antibodies and CAR-T cells are also being explored in front-line settings, though reducing their infectious complications is still under investigation.

29 June 2026 in Clinical Hematology International
Verified
Journal Article
Open access
Sofia Isabel Quezada-RamirezSofia Isabel Quezada-Ramirez
Sofia Isabel Quezada-Ramirez
JMJosé E. Montelongo-Cepeda
José E. Montelongo-Cepeda
GGGabriel A. González-López
Gabriel A. González-López
RSRosario Salazar-Riojas
Rosario Salazar-Riojas
DADalila M. Alvarado-Navarro
Dalila M. Alvarado-Navarro
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative treatment for patients with relapsed or refractory hematologic malignancies, offering new possibilities beyond conventional transplantation. Since their approval in high-income countries, CAR-T products have demonstrated remarkable efficacy; however, their implementation in low- and middle-income countries (LMICs) remains limited due insufficient infrastructure, complex regulatory requirements and high costs. In some countries, like Mexico, these barriers are particularly pronounced, with limited access to clinical-grade vectors, early phase clinical research programs, and lack of government and private sector infrastructure and funding opportunities. Facing these challenges, there is a substantial patient population with B-cell acute lymphoblastic leukemia, multiple myeloma, or diffuse large B-cell lymphoma, who could benefit from CAR-T therapy. Advances in point-of-care manufacturing within academic settings –particularly the use of closed, semi-automated systems– have demonstrated feasibility in LMICs, by reducing costs and simplifying procedures, while maintaining product quality. These approaches may provide a viable alternative to commercial products, with the potential to lower the economic burden and increase accessibility. Regulatory innovation with the establishment of expert multidisciplinary oversight committees, will also be critical to ensure safe implementation. Ultimately, CAR-T therapy in LMICs is both a scientific and public health opportunity, and its integration into healthcare systems will depend on collaborative strategies that address financial, logistical, and policy barriers. By highlighting our experience, this review underscores the importance of developing locally adapted solutions to expand access to advanced cellular therapies in resource-constrained settings.